JNJ-5939

Product Description

NM26-2198 is a bispecific antibody which targets IL-4Ralpha (type I and type II receptors) and IL-31 for the treatment of atopic dermatitis, or AD. NM26-2198 is designed to prevent IL-4/IL-13 and IL-31-induced keratinocyte immunopathology, immune cell activation, skin barrier function impairment and pruritis, all of which are hallmarks of the pathophysiology of atopic dermatitis. The targeting of the IL-4/IL-13 pathway is well established for the treatment of AD and other inflammatory diseases, with therapies such as dupilumab, marketed as Dupixent, demonstrating both clinical efficacy and the size of the potential market opportunity. We believe that adding IL-31 mediated blockade of neuroinflammation to the repression of Th2 driven inflammation by IL-4/IL-13 blockade could enable a faster onset of action and improved efficacy compared to the current standard of care in AD, together with convenient subcutaneous administration. Numab develops this program together with its Japanese partner Kaken Pharmaceutical Co., Ltd. (Sourced from: https://www.numab.com/pipeline/)

Mechanisms of Action: IL4 Inhibitor, IL31 Inhibitor

Novel Mechanism: No

Modality: Bispecific Antibody

Route of Administration: Subcutaneous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Johnson & Johnson
Company Location: Eastern America
Company Founding Year: 1886
Additional Commercial Interests: Numab Therapeutics